Xconomy Seattle

Spaltudaq Now Theraclone Sciences

Luke Timmerman3/30/09

Spaltudaq (SPAHL-too-dack), the Seattle-based maker of genetically engineered antibody drugs, has changed its name to Theraclone Sciences. Founder Johnny Stine, a member of the Snohomish tribe, gave the company its original name after a healing ceremony once performed by his ancestors in the Puget Sound region to make sure people don’t die before their time. The new name was chosen to “highlight our ability to clone and express clinically relevant, naturally fully human antibodies for clinical and commercial benefit,” said CEO David Fanning.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.